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ABSTRACT
Introduction: Lower respiratory infections (LRIs) and
pneumonia are among the leading causes of death
worldwide, especially in children aged under 5 years,
and these patterns are reflected in the South African
population. Local epidemiological data for LRIs and
pneumonia are required to inform the Second National
Burden of Disease Study underway in South Africa.
The aim of this systematic review is to identify
published studies reporting the prevalence, incidence,
case fatality, duration or severity of LRI and pneumonia
in adults and children in South Africa.
Methods and analysis: Electronic database searches
will be conducted to obtain studies reporting on the
prevalence, incidence, case fatality, duration and
severity of LRI and pneumonia in South Africa between
January 1997 and December 2015. Studies that are
assessed to have moderate or low risk of bias will be
included in a meta-analysis, if appropriate. Where
meta-analysis is not possible, the articles will be
described narratively. Subgroup analysis (eg, age
groups) will also be conducted where enough
information is available.
Ethics and dissemination: This systematic review
will only include published data with no linked patient-
level information; thus, no ethics approval is required.
The findings will be used to calculate the burden of
disease attributed to LRI and pneumonia in South
Africa and will highlight the type of epidemiological
data available in the country. The article will be
disseminated in a peer-reviewed publication.
PROSPERO registration number:
CRD42016036520.
INTRODUCTION
Pneumonia is a common lower respiratory
infection (LRI).1 Even though clear deﬁni-
tions do exist, the distinction between LRIs
and pneumonia is often ambiguous as the
terms are used interchangeably by research-
ers. In 2013, the Institute for Health Metrics
and Evaluation (IHME) Global Burden of
Disease (GBD) study found that LRIs
accounted for 2.7 million deaths worldwide.2
They also reported that pneumonia was the
leading cause of death in children aged
under 5 years and contributed to 14% of
total child deaths globally in 2013.3 Although
pneumonia can affect people of all ages, chil-
dren aged under 5 years, adults over 65 years
and immunocompromised persons tend to
be more at risk.4 The majority of pneumonia
mortality (81%) occurs within the ﬁrst
2 years of life.5 Globally, it has been esti-
mated that ∼12% of pneumonia episodes
progress to severe episodes in children.5
Pneumonia is an acute form of respiratory
tract infections whereby the lung alveoli
become ﬁlled with ﬂuid, causing painful
breathing and limiting oxygen intake.4
Various pathogens cause pneumonia, the
Strengths and limitations of this study
▪ To the best of our knowledge, this will be the
first systematic review on lower respiratory infec-
tion (LRI) and pneumonia in South Africa.
▪ This review should provide epidemiological para-
meters necessary to model disease burden due
to LRI and pneumonia in South Africa.
▪ The protocol conforms to the Preferred
Reporting Items for Systematic reviews and
Meta-Analyses (PRISMA-P 2015) guidelines.
▪ Depending on whether very wide or narrow case
definitions are used for LRI and pneumonia, the
burden of disease may be overestimated or
underestimated and varying case definitions may
limit comparison across studies.
▪ All observational studies will have the robustness
of their methods examined by using a
risk-of-bias-tool and studies will be excluded if
they have a high risk of bias as they may limit
this study.
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most common being bacterial (eg, Streptococcus pneumo-
niae, Haemophilus inﬂuenzae type b (Hib)) or viral (eg,
respiratory syncytial virus (RSV)).4 The pathogens that
cause pneumonia vary by a number of factors; these
include: age (eg, RSV commonly affects children aged
under 2 years,4 S. pneumoniae appears to be the most
common bacterial cause in children in the developing
world4 6 and community-acquired pneumonia (CAP) in
the elderly);7 and HIV status (Pneumocystis jirovecii (previ-
ously P. carinii) pneumonia is a common opportunistic
infection and substantial cause of mortality in
HIV-positive individuals).8 Nevertheless, identifying spe-
ciﬁc causal pathogens (especially bacteria) in children
can be difﬁcult, as the identiﬁcation of a pathogen does
not establish causality. Furthermore, mixed viral and bac-
terial infections are known to occur simultaneously.9
Deﬁnite risk factors for children in developing coun-
tries include malnutrition, low birth weight, non-
exclusive breast feeding (ﬁrst 4 months of age), lack of
measles immunisation (ﬁrst 12 months of age), indoor
air pollution and crowding.10 Possible risk factors
include mother’s education, day care attendance,
vitamin A deﬁciency, birth order, and environmental
factors such as humidity, high altitude and outdoor air
pollution.1 10 Other likely risk factors include: parental
smoking, zinc deﬁciency, concomitant diseases (eg, diar-
rhoea, asthma), etc.1 10 The elderly are more prone to
developing severe disease as their immunity and lung
function tend to be compromised due to the ageing
process.7 In addition, swallowing disorders, malnutrition,
comorbidities (eg, diabetes, renal disease) and inactivity
(bedridden status) also predispose the elderly to acquir-
ing CAP.7 Immunosuppression can increase the risk of
developing pneumonia at any age.4
LRIs and pneumonia in South Africa
Pneumonia is a major reason for health facility usage in
low and middle income countries.5 The sub-Saharan
African and South Asian regions have been dispropor-
tionally affected by deaths from pneumonia in children
aged under 5 years.3 The ﬁrst South African National
Burden of Disease (SANBD-1) study ranked LRIs as the
sixth leading cause of premature mortality in South
Africa contributing to 3.8% of the years of life lost
(YLLs) in the country in 2000.11
The second SANBD (SANBD-2) study,12 currently
underway, intends to estimate the disease burden for the
country using summary measures of population health
for the years 1997–2012. The health loss from premature
mortality (YLLs) needs to be combined with the loss of
healthy life due to disability or morbidity from non-fatal
outcomes (years lived with disability, YLD) in order to cal-
culate the disability-adjusted life years (DALYs).13 The
SANBD-2 has estimated the YLLs using vital registration
and other data sources.14 In order to calculate the YLDs
due to LRI and pneumonia, nationally representative epi-
demiological data are needed. If these are not available,
ﬁndings from smaller studies can be included to estimate
YLDs using a pooled meta-analysis. The YLD component
can be estimated through disease modelling of at least
three epidemiological parameters (prevalence, incidence,
case fatality, duration or severity) pertaining to LRIs and
pneumonia in South Africa. To the best of our knowl-
edge, no systematic reviews have been conducted to deter-
mine the prevalence, incidence, case fatality, duration or
severity of LRIs and pneumonia in South Africa.
AIM
In order to present evidence on epidemiological para-
meters relating to LRI and pneumonia in South Africa,
a systematic literature review will be conducted to iden-
tify published studies that report the prevalence, inci-
dence, case fatality, duration or severity of LRI and
pneumonia. Furthermore, this review will also report on
the variation of deﬁnitions used to describe LRI and
pneumonia. The ﬁndings from this review will be used
to estimate the morbidity burden due to LRI and pneu-
monia (to generate YLDs and DALYs) in South Africa.
METHODS
Eligibility criteria
Studies will be selected according to the criteria out-
lined below.
Types of participants
Studies assessing the epidemiology (prevalence, inci-
dence, case fatality, duration or severity) of LRI and
pneumonia, in children and adults from anywhere in
South Africa, will be included.
Case definition
The deﬁnitions for LRI and pneumonia can be prob-
lematic.14 15 Pneumonia in children is a diagnosis made
on tissue pathology and thus there is no clinical deﬁn-
ition that is completely accurate.9 The WHO’s case def-
inition for childhood pneumonia is widely used in
resource-poor settings,16 although it lacks speciﬁcity.14
Deﬁnitions also vary by age group. Included studies
should clearly state a case deﬁnition for LRI and pneu-
monia, whether it be a clinical description, radiological,
laboratory-based or International Classiﬁcation of
Diseases (ICD) codes. Owing to variations in LRI and
pneumonia deﬁnitions, we will extract the deﬁnitions as
reported in individual studies (whether clinical descrip-
tion, radiological, laboratory-based or ICD codes).
Although LRIs and pneumonia are among the most
common diseases in the world, many other conditions
(eg, malaria, bacterial sepsis, severe anaemia) produce
clinical symptoms that signiﬁcantly overlap with those of
LRIs and pneumonia and thus differentiating between
conditions can be a challenge.14 This will be evaluated
by carefully assessing the appropriateness of case deﬁn-
ition in consultation with respiratory disease experts,
and methodologies used by studies (eg, whether the
investigator attempted to exclude bronchiolitis, sepsis,
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pertussis, measles, asthma, malaria or neonatal sepsis in
children9).
Inclusion criteria
Studies will be included if they are conducted in South
Africa, report one of the primary outcomes (listed
below) and report a clear case deﬁnition for LRI and
pneumonia.
Exclusion criteria
Studies will be excluded from this review if they are not
conducted in South Africa, do not report any of the
primary outcomes (listed below) and have no clear case
deﬁnition for LRI and pneumonia.
Outcomes
Primary outcome
The primary outcomes of interest are prevalence, inci-
dence, case fatality, duration or severity of LRI and
pneumonia.
Owing to the acute nature of LRI and pneumonia,
especially in children, incidence rather than prevalence
is used to estimate the burden of the disease. In chronic
cases, incidence and prevalence are appropriate.
Therefore, both terms (ie, ‘incidence’ and ‘prevalence’)
will be included in the search strategy to ensure that no
relevant studies are unintentionally excluded.
For this review, the deﬁnitions for prevalence, incidence,
case fatality and duration will be adapted from Bonita
et al,17 Giesecke18 and Joubert et al.19 Prevalence is
deﬁned as the number of people with disease (LRI and
pneumonia) at a speciﬁed time divided by the popula-
tion at risk at the speciﬁed time. The point prevalence
rate refers to data collected at one point in time and the
period prevalence rate refers to the total number of
cases at any time during a speciﬁed period, which is
then divided by the population at risk midway through
the period.17 The incidence of LRI and pneumonia
refers to the number of new cases occurring in a popula-
tion.17 Cumulative incidence is often measured over a
longer period18 and refers to the number of people who
get a disease during a speciﬁed period divided by the
number of people free of disease at the start of the
period,17 while the incidence rate (or incidence density)
is the number of new cases in a speciﬁed time period
divided by the total disease-free person-time of observa-
tion in the at-risk population. Case fatality refers to the
percentage of cases with disease (LRI and pneumonia)
who died of the disease out of those who contracted it.18
In terms of LRI and pneumonia, the deﬁnition for dur-
ation refers to the average duration spent in the diseased
state, as described by the DisMod II help guide.20
Severity refers to the proportion of severe cases of LRI
and pneumonia from a deﬁned population with LRI
and pneumonia. Studies may deﬁne severity differently.
Studies on children may use the WHO Integrated
Management of Childhood Illness (IMCI) classiﬁca-
tion21 which includes only two categories of pneumonia:
1. Pneumonia: pneumonia with fast breathing and/or
chest in-drawing that can be treated at home with
oral amoxicillin.
2. Severe pneumonia: pneumonia with any general
danger signs which requires referral and injectable
treatment.
Studies on adults may use the CURB-65 score to classify
the severity of CAP.22 Each component has a score of 1
and if a patient scores either 0 or 1, they are classiﬁed as
mild and can be treated at home (depending on social
circumstances). If the patient scores 2, they are classiﬁed
as moderately ill and hospital treatment may be necessary,
while a score of ≥3 implies severe pneumonia.22 23
Secondary outcome
A narrative comparison of case deﬁnitions for all
included studies that describe how LRI and pneumonia
are deﬁned.
Types of studies
We will include published population-based surveys,
cross-sectional studies, prospective or retrospective
cohort studies, case–control studies and studies on sur-
veillance systems. Interventions studies, studies on diag-
nostic accuracy and grey literature will be excluded.
Studies that include South Africa will be reviewed and
only the South African data will be added to the review.
Studies based on miners due to their speciﬁc exposure
will be excluded.24 25 All English studies published from
January 1997 to December 2015 will be included.
Search strategy
A comprehensive search strategy will be formulated.
Disease content experts will be contacted to ensure that
the search terms are relevant and optimal for our pur-
poses. The search strategy will be modiﬁed, where neces-
sary, according to the database or search engine used.
Disease content experts will also be contacted to identify
studies that they deem relevant. An example search strat-
egy is shown in ﬁgure 1.
Electronic databases
The following electronic databases and search engines
will be used: PubMed, Scopus, Science Direct, JSTOR,
POPLINE, Web of Science, CINAHL and African Index
Medicus.
Selection of eligible studies
Two researchers will independently screen the titles and
abstracts from the search output against the inclusion
criteria to identify potentially eligible studies. These
studies will have their full-texts retrieved and independ-
ently reviewed for inclusion. Additional information will
be requested from study authors where required. Any
disagreements will be resolved through discussion
between the two researchers. Reasons for exclusion will
be recorded. The researchers will not be blinded to
journal titles, study authors or institutions.
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Data collection process
Relevant information will be independently extracted
from included studies and recorded using an electronic
system (the Burden of Disease Review Manager). Once
completed, the reviewers will compare the data extracted
and any disagreements will be resolved through
consensus. If no agreement can be reached, a third
researcher will be consulted. If needed, authors of
studies will be contacted for additional information. The
following data will be extracted:
▸ Study details: year of study publication, study design,
study period and study purpose.
Figure 1 Search strategy.
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▸ Study population: country/province/district of study,
study setting (community or health facility based).
▸ Case deﬁnition: as reported in study.
▸ Prevalence, incidence, case fatality, duration, severity
of LRI and pneumonia; and deﬁnitions used to
describe these parameters.
▸ Characteristics of cases: age, sex, vaccination status,
comorbid diseases (eg, HIV status).
Risk-of-Bias quality assessment
Two researchers will independently assess the risk of bias
of each study using a modiﬁed checklist.26 This checklist
was created by adapting the risk-of-bias tool for
population-based prevalence studies described by Hoy
et al,27 and the Newcastle-Ottawa Scale for assessing the
quality of non-randomised studies.28 This new checklist
(tool) was pretested and modiﬁed to suit our context.
The tool assesses both internal and external validity, and
each item is assigned a maximum score of four or
minimum score of zero, depending on the question.
The overall quality score ranges from 1 to 20 (high
risk=1 to 6; moderate risk=7 to 13; low risk=14 to 20).
The researchers will discuss and resolve any discrepan-
cies between their independent assessments and assign
the study a ﬁnal score. Studies deemed to be of poor
methodological quality will be excluded and the reasons
for exclusions will be noted.
Data synthesis
Only studies assigned to moderate or low risk in the
risk-of-bias quality assessment will be included in the
analysis. Case deﬁnitions along with other data will be
presented in a narrative synthesis and tabulated.
In the event that the generated data are amenable to
meta-analysis, we will perform separate meta-analyses for
each of the epidemiological parameters using Stata 13
(College Station, Texas). We will pool estimates across
studies and obtain an overall summary estimate and
95% CI. Clinical heterogeneity will be judged by the dif-
ferences in types of participants and case deﬁnitions
used for LRI and pneumonia. Statistical heterogeneity
will be assessed using χ2 test. The statistically signiﬁcant
heterogeneity will be considered existent when χ2
p≤0.10.29 30 The I2 statistic will be used to determine the
degree of heterogeneity. If the study results are found to
be statistically homogeneous (ie, when χ2 p>0.10), we
will pool them using the ﬁxed-effect meta-analysis.
Otherwise, we will use random-effects meta-analysis.
Publication bias will be assessed by visual inspections of
funnel plots, provided that there are at least 10 studies.31
The results will be presented in a systematic narrative
synthesis when it is not possible to pool the data. This
will be used to summarise each study’s ﬁndings and simi-
larities and differences between included studies.
Where possible, a trend analysis will be conducted to
explore the epidemiological parameters of LRI and
pneumonia in South Africa over time, taking the intro-
duction of Prevention of Mother to Child Transmission
of HIV (PMTCT), seasonality and vaccines into account.
When analysing data, care will be taken to identify
trends in the light of historical changes in the vaccin-
ation programme in South Africa, namely changes over
time in Hib, pneumococcal conjugate vaccine-7
(PCV-7), rotavirus vaccinations, pertussis vaccine, Hib
booster and the PCV-13.
Subgroup analysis
Where sufﬁcient data exist, subgroup analysis will be
conducted based on case deﬁnition criteria (eg, clinical
description, radiological, laboratory based or ICD
codes), setting (eg, community or health facility, geo-
graphical location), age groups (eg, children and adults
aged >65 years), cases with comorbidities (eg, HIV) and
time periods (eg, periods that certain vaccinations were
introduced vs years prior to that vaccination; study
periods for seasonality).
Confidence in cumulative evidence
The main ﬁndings will be summarised and include the
strength of evidence using the Grading of
Recommendations Assessment, Development and
Evaluation (GRADE) approach.32 GRADE classiﬁes evi-
dence into four levels (high, moderate, low and very
low) based on study limitations, inconsistency of results,
indirectness of evidence, imprecision and reporting bias.
GRADE also allows for either ‘strong’ or ‘weak’ recom-
mendation based on the strength of the evidence and
other related factors.
Amendments to the protocol
Should protocol amendments occur, these will be dated
together with a description and reason for the change.
ETHICS AND DISSEMINATION
This study will use the results of other published studies
which cannot be linked to individuals and thus does not
require ethics approval. The ﬁndings will be used to cal-
culate the burden of disease attributed to LRI and pneu-
monia in South Africa and will highlight the type of
epidemiological data available in the country. The esti-
mated burden of disease due to LRI and pneumonia
will be important in guiding policymakers. The ﬁndings
of the systematic review will be written up in accordance
with the Preferred Reporting Items for Systematic
Review and Meta-Analysis Protocols (PRISMA-P) 2015
guidelines.
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